Tag Index  /  Showing 1 - 15 of 15 results for “23andMe”

Government Healthcare

FDA Greenlights 23andMe and Opens New Era for Consumer DNA Info

It was a much-needed breakthrough when the FDA last week OK'd personal genomics company 23andMe selling genetic tests directly to consumers. In 2013 the agency had banned the startup from releasing disease-related information. Now we should finally see a consumer-driven marketplace for genomic data.   More

Analytics & Data Bio & Life Sciences

23andMe’s Community Wants to Help, CEO Tells Genomics Researchers

At a genomics conference in February, 23andMe CEO Anne Wojcicki took the stage to make the case for the scientific importance of her consumer genetics platform. Wojcicki still has a grand vision for how the service could help advance our understanding of human health, even as she acknowledges that recent restrictions imposed on the company by the FDA have left her more cautious about growth plans for 23andMe.   More

Bio & Life Sciences Global Tech Internet of Things

Techonomy’s Top Articles for 2015

At Techonomy we put on conferences and publish articles and videos. Our most popular articles this year tackled the conceptual problem with the Apple Watch, the Human side of the Internet of Things, how consumer genomics empowers consumers, tech and artificial intelligence progress in Ethiopia, and the need for the biotech industry to step up its game in communicating to the general public. It's a good flavor of the range of issues and topics that fascinate and motivate us. Keep with us in 2016 for much much more!   More

Bio & Life Sciences

5 Genomic Advances To Be Thankful For

With Thanksgiving approaching, Techonomy's resident champion of genomics details some things she's thankful for this year: Better Cancer Testing; Increased Data-Sharing Efforts; Scientists Who Push Boundaries (and Police Themselves Too); Living Foundries; and the FDA's Approval of the First DTC Genetic Test. She looks forward to more advances that will help regular consumers as programs like the federal Precision Medicine Initiative kick off.   More

Analytics & Data Bio & Life Sciences

How to Get and Protect Your Genetic Data

Maybe it was the Jolie effect. Or you want to find out if you’re carrying a silent genetic mutation that could be passed on to a child. Or perhaps you’re just really hoping you can blame your DNA for how awful cilantro tastes. Whatever the reason, you’re interested in finding out something about your genome. Now what? Though consumer genetic testing and personal genome sequencing are still nascent fields, every indication suggests that the public will have a virtually insatiable appetite for genetic data. And as scientists get better at establishing links between DNA and diseases or specific traits, that demand will only increase. But are we ready for this data?   More

Bio & Life Sciences Healthcare

Are 23andMe Customers Suckers or Empowered Consumers?

Direct-to-consumer genomics company 23andMe announced two research partnerships with pharmaceutical companies earlier this month. Since then, a lot of pundits have sounded positively appalled by the development. It reminds me of that great scene in "Casablanca" when Captain Renault says, “I’m shocked—shocked—to find that gambling is going on in here!” as he collects his own winnings.   More

Bio & Life Sciences

Talking to “Biologist’s Imagination” Author William Hoffman

In a new book called "The Biologist’s Imagination," authors William Hoffman and Leo Furcht from the University of Minnesota Medical School take a spin through the history of biological innovation in an effort to shed light on current trends and expected future developments. The authors weave historical threads—such as pioneering studies of genetic traits in the mid-19th century and the effects of the animals and diseases brought to the Americas in the wake of Columbus crossing the Atlantic—to help readers make sense of what’s happening today.The book covers a number of topics relevant to Techonomy, so we chatted with Hoffman to find out more.   More

Bio & Life Sciences

How You Are Hurt by FDA Genetic Test Restrictions

These are boom times for progress in genetic testing, but restrictions limiting access are delaying benefits we could all be experiencing right now. The National Institutes of Health maintains a Genetic Testing Registry, which currently lists some 15,000 available genetic tests. Together, they can single out 2,800 genes for some 4,000 medical conditions—and that’s not factoring in the rapidly growing exome or genome sequencing tests that look at all known genes. With so many tests out there, there’s a good chance that one exists to scan for whatever diseases may run in your family. But you may not be able to get those tests. Direct consumer access has always been tricky in U.S. medicine, and the FDA’s crackdown on consumer genetic testing firm 23andMe last year has providers running scared.   More

Bio & Life Sciences Business Internet of Things Security & Privacy

People, Companies, and Trends: Techonomy’s 2013 Top Ten

As 2013 winds down, Techonomy takes a moment to look back on highlights from the year, especially those that portend—we think—the future. Our Top Ten list recognizes the people, companies, and ideas that embodied how technology is catalyzing change in business and society. Some of the individuals and organizations here were represented at our 2013 conferences, labs, and dinners, where we convene leaders to explore the biggest tech-driven challenges and opportunities. Some were featured in our expanding online editorial content.   More

Analytics & Data Bio & Life Sciences Business

23andMe’s FDA Battle Provokes Furious Debate

Medical researchers, genomics experts, and industry pundits took wildly divergent points of view in a media storm that erupted last week over FDA’s stern letter ordering 23andMe to stop marketing its Personal Genome Service. The agency cited concerns about “the public health consequences of inaccurate results.” Others say public access to genomic information is just the beginning of ongoing disruption in healthcare.   More

Bio & Life Sciences Business

FDA Tells 23andMe to Stop Selling DNA Tests

Citing concerns "about the public health consequences of inaccurate results" from its Personal Genome Service, the FDA on Friday told 23andMe CEO Ann Wojcicki in a stern Warning Letter that her company must "immediately discontinue marketing" the service "until such time as it receives FDA marketing authorization for the device." The Twittersphere responded with shock and some outrage.   More

Bio & Life Sciences

Are Flash Sales Coming to Consumer Genomics?

Could consumers be persuaded to snatch up DNA sequences as must-have accessories? With former Gilt Groupe President Andy Page in a new leadership role, 23andMe might be able to swing that. The personal genetics company began late last year offering its Personal Genome service for $99 and set a goal to serve 1 million customers in 2013.   More

Bio & Life Sciences

Holiday Gift Ideas for Techonomic People

With the holidays drawing near, we thought it was the perfect time to look at the top items on any Techonomic wishlist—gifts that make the most of advances in science and technology to help build a better life. Whether “better” means fuller, healthier, or simply more fun is entirely up to you.   More

Bio & Life Sciences

Consumer Genetics Starts to Pay Off

One of the biggest hopes when the $3 billion Human Genome Project launched two decades ago was that it would one day put lots of basic genetic information into the hands of the general public. It's taken a long time, and many argue that the whole project was a waste of money. But in research labs and technology incubators, real advances are underway. The nascent field of consumer genetics is starting to fulfill the potential of the Human Genome Project.   More

Bio & Life Sciences

23andMe Opens Up to App Developers, But Beware

If you've had your genome sequenced, there will soon be apps for that. Personal genome sequencing company 23andMe this week opened up its application program interface to allow third-party developers to build "a broad range of new applications and tools for the 23andMe community generated from the company’s data sets."   More